Bausch Health Companies (BHC) Research & Development (2009 - 2026)

Bausch Health Companies has disclosed Research & Development across 18 years of filings, most recently posting $173.0 million for Q2 2026.

• In Q2 2026, Research & Development rose 8.81% year-over-year to $173.0 million; the TTM figure through Jun 2026 stood at $663.0 million (up 8.51% YoY), while the FY2025 annual figure was $629.0 million, up 2.11% from the prior year.
• Research & Development came in at $173.0 million for Q2 2026 at Bausch Health Companies, up from $163.0 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $173.0 million in Q2 2026 to a low of $127.0 million in Q1 2022.
• Average Research & Development over 5 years is $150.8 million, with a median of $152.5 million recorded in 2023.
• Year-over-year, Research & Development gained 22.83% in 2023 and retreated 5.3% in 2025.
• Over 5 years, Research & Development stood at $142.0 million in 2022, then gained by 7.04% to $152.0 million in 2023, then climbed by 7.24% to $163.0 million in 2024, then declined by 1.23% to $161.0 million in 2025, then grew by 7.45% to $173.0 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $173.0 million in Q2 2026, $163.0 million in Q1 2026, and $161.0 million in Q4 2025.